Epilepsy: Emerging Therapies

Call for Papers

According to a 2012 IOM report, epilepsy is one of the most common neurologic conditions in the United States, affecting at least 1 in 100 adults and 1 in 20 children. Although many patients achieve full control of seizures through commercially available antiepileptic medications, up to 35% of patients experience recurrent seizures that limit their functional ability and decrease their quality of life. The improved understanding of epilepsy resulting from research has led to many potential new treatments. Some of these treatments are now commercially available. Others are now in clinical trials, while others are still in early development. If these treatments work as anticipated, they should greatly improve the care of people with epilepsy.

We invite investigators to contribute original research articles as well as review articles that focus on the emerging treatments for epilepsy. Potential topics include, but are not limited to:

• New pharmacologic agents
• Novel surgical procedure or techniques
• Advances in genetics and gene therapy
• Novel hormonal or diet therapy
• Invasive and noninvasive brain stimulation, vaccines, and therapies to predict and abort seizures

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ert/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/ert/eet/ according to the following timetable:

Lead Guest Editor

• Jerry J. Shih, Comprehensive Epilepsy Program, Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA

Guest Editors

• Jeffrey Buchhalter, University of Calgary, Calgary, AB, Canada
• Nathan Fountain, Comprehensive Epilepsy Program, University of Virginia, Charlottesville, VA, USA
• R. Edward Hogan, Comprehensive Epilepsy Program, Washington University, St. Louis, MO, USA